Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 433 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "biochemical recurrence" Clear all
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

NCT01853878
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 27, 2026, 9:54 PM EDT
Not listed Phase 2 Interventional

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

NCT03141671
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH, Bicalutamide, Salvage radiation, Abiraterone, Prednisone, Apalutamide
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 95 Years · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 27, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT03396874
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68Ga-PSMA
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
1,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 27, 2026, 9:54 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

NCT04452136
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68GA PSMA-HBED-CC
Drug
Lead sponsor
Jeanne Link
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 27, 2026, 9:54 PM EDT
Terminated Phase 4 Interventional Results available

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

NCT01147042
View directory record Official record
Conditions
IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
Interventions
IFN-gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 27, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

NCT00796445
View directory record Official record
Conditions
Melanoma
Interventions
GSK 2132231A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
74
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 27, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 27, 2026, 9:54 PM EDT
Withdrawn No phase listed Observational

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

NCT03182049
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Airway assessment, Rheumatology assessment
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 27, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

NCT01685255
View directory record Official record
Conditions
Ovarian Cancer, Genitourinary (GU) Tumors
Interventions
Epacadostat, tamoxifen
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT02918357
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

68Ga-PSMA-11 PET in Patients With Prostate Cancer

NCT05197257
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Ga-PSMA-11
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 27, 2026, 9:54 PM EDT
Withdrawn Not applicable Interventional

Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

NCT04486846
View directory record Official record
Conditions
Prostate Cancer
Interventions
eVisit
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Cary, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 27, 2026, 9:54 PM EDT
Suspended Phase 2 Interventional

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT04519879
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Clinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Duarte, California • Glendora, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 27, 2026, 9:54 PM EDT
Not listed Phase 3 Interventional Results available

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

NCT00667888
View directory record Official record
Conditions
Prostate Cancer
Interventions
Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

NCT00108732
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, Sargramostim
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 27, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 27, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Not applicable Interventional

EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

NCT04266431
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
EMPOWER
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 27, 2026, 9:54 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
Drug · Other
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years to 75 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 27, 2026, 9:54 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 27, 2026, 9:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 27, 2026, 9:54 PM EDT